Program
avacincaptad pegol
Also written as “Avacincaptad Pegol”, “Izervay™” and “Zimura”.
Its studies are mostly in Geographic Atrophy · Macular Degeneration · Polypoidal Choroidal Vasculopathy · Stargardt Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 101 open or running | phase 4since May 6, 2025 | Jul 1, 2008 | Jun 30, 2027phase 4 · NCT06970665 |
| Hoffmann-La Roche | 10 open or running | phase 1since Apr 29, 2025 | Apr 29, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2008First study: phase 1 study in Neovascular Age-Related Macular DegenerationNew to Astellas PharmaAstellas Pharma · NCT00709527 · 60 enrolled · United States
- Jul 30, 2009Phase 1 study in Dry Age-Related Macular DegenerationAstellas Pharma · NCT00950638 · 47 enrolled · United States
- Mar 19, 2015Phase 2 study in Polypoidal Choroidal VasculopathyAstellas Pharma · NCT02397954 · 4 enrolled · United States
- Feb 16, 2016Phase 3 study in Geographic AtrophyAstellas Pharma · NCT02686658 · 286 enrolled · United States, Croatia, Czechia and more
- Oct 30, 2017Phase 2 study in Neovascular Age-related Macular DegenerationAstellas Pharma · NCT03362190 · 64 enrolled · United States, Hungary, Latvia
- Dec 1, 20172 phase 2 studiesAstellas Pharma · NCT03364153, NCT03374670
- May 12, 2020Phase 3 study in Geographic AtrophyAstellas Pharma · NCT04435366 · 448 enrolled · United States, Argentina, Australia and more
- Sep 7, 2022Phase 3 study in Geographic AtrophyAstellas Pharma · NCT05536297 · 278 enrolled · United States, Argentina, Australia and more
- Apr 29, 2025Hoffmann-La Roche's first study: phase 1 study in Geographic AtrophyNew to Hoffmann-La RocheHoffmann-La Roche · NCT06961370 · 27 enrolled · United States
- May 6, 2025Phase 4 study in Geographic AtrophyAstellas Pharma · NCT06970665 · 17 enrolled · Japan
Ahead
- Jun 30, 2027Primary completion: phase 4 study in Geographic AtrophyAstellas Pharma · NCT06970665
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06970665Geographic Atrophy · Japan | 4 | Active, not recruiting | Astellas Pharma | Jun 30, 2027 | 17 |
| NCT06961370Geographic Atrophy · United States | 1 | Terminated | Hoffmann-La Roche | Feb 3, 2026 | 27 |
| NCT05536297Geographic Atrophy · United States, Argentina, Australia and more | 3 | Completed | Astellas Pharma | Apr 10, 2025 | 278 |
| NCT04435366Geographic Atrophy · United States, Argentina, Australia and more | 3 | Completed | Astellas Pharma | Jul 25, 2022 | 448 |
| NCT03374670Polypoidal Choroidal Vasculopathy · United States | 2 | Withdrawn | Astellas Pharma | Dec 2019 | 0 |
| NCT03364153Stargardt Disease · United States, France, Germany and more | 2 | Completed | Astellas Pharma | Mar 31, 2025 | 121 |
| NCT03362190Neovascular Age-related Macular Degeneration · United States, Hungary, Latvia | 2 | Completed | Astellas Pharma | Oct 18, 2018 | 64 |
| NCT02686658Geographic Atrophy · United States, Croatia, Czechia and more | 3 | Completed | Astellas Pharma | Sep 26, 2019 | 286 |
| NCT02397954Polypoidal Choroidal Vasculopathy · United States | 2 | Completed | Astellas Pharma | Oct 23, 2015 | 4 |
| NCT00950638Dry Age-Related Macular Degeneration · United States | 1 | Completed | Astellas Pharma | Mar 24, 2011 | 47 |
| NCT00709527Neovascular Age-Related Macular Degeneration · United States | 1 | Completed | Astellas Pharma | Dec 30, 2009 | 60 |
How it is read
Names in the registry
- “Avacincaptad Pegol”, 6 entries
- “avacincaptad pegol”, 3 entries
- “Izervay™”, 1 entry
- “Zimura”, 1 entry
Conditions, from the studies’ own filings
- Geographic Atrophy, 5 studies
- Macular Degeneration, 3 studies
- Polypoidal Choroidal Vasculopathy, 2 studies
- Stargardt Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.